Possible mechanisms associated with immune escape and apoptosis on anti-hepatocellular carcinoma effect of Mu Ji Fang granules.

H22 tumor-bearing mice HepG2 cells Hepatocellular carcinoma Immune escape Mu Ji Fang granules Transforming growth factor β1/Mothers against decapentaplegic homolog

Journal

World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470

Informations de publication

Date de publication:
15 Mar 2023
Historique:
received: 20 12 2022
revised: 19 01 2023
accepted: 02 03 2023
medline: 4 4 2023
entrez: 3 4 2023
pubmed: 4 4 2023
Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC) is one of the most common digestive system cancers with high mortality rates worldwide. The main ingredients in Mu Ji Fang Granules (MJF) are alkaloids, flavonoids, and polysaccharides. MJF has been used in the clinical treatment of hepatitis, cirrhosis and HCC for more than 30 years. Few previous studies have focused on the mechanism of MJF on tumor immu-nology in the treatment of HCC. To explore the mechanism of action of MJF on tumor immunology in the treatment of HCC. The absorbable ingredients of MJF were identified using Molecule Network related to High Performance Liquid Chromatography-Electron Spray Ionization-Time of Flight- Mass Spectrometry, and hub potential anti-HCC targets were screened using network pharmacology and pathway enrichment analysis. Forty male mice were randomly divided into the Blank, Model, and MJF groups (1.8, 5.4, and 10.8 g/kg/d) following 7 d of oral administration. Average body weight gain, spleen and thymus indices were calculated, tumor tissues were stained with hematoxylin and eosin, and Interferon gamma (IFN-γ), Tumor necrosis factor α (TNF-α), Interleukin-2, aspartate aminotransferase, alanine aminotransferase, alpha-fetoprotein (AFP), Fas, and FasL were measured by Enzyme-linked Immunosorbent Assay. Relevant mRNA expression of It was shown that MJF improved body weight gain and tumor inhibition rate in H22 tumor-bearing mice, protected immune organs and liver function, reduced the HCC indicator AFP, affected immunity and apoptosis, and up-regulated the TGF-β1/SMAD signaling pathway, by increasing the relative expression of TGF-β1, SMAD2, p-SMAD2 and SMAD4 and decreasing SMAD7, reducing immune factors TNF-α and IFN-γ, decreasing apoptosis cytokines Fas, FasL and MJF inhibits HCC by activating the TGF-β1/SMAD signaling pathway, and affecting immune and apoptotic cytokines, which may be due to MJF adjusting immune escape and apoptosis.

Sections du résumé

BACKGROUND BACKGROUND
Hepatocellular carcinoma (HCC) is one of the most common digestive system cancers with high mortality rates worldwide. The main ingredients in Mu Ji Fang Granules (MJF) are alkaloids, flavonoids, and polysaccharides. MJF has been used in the clinical treatment of hepatitis, cirrhosis and HCC for more than 30 years. Few previous studies have focused on the mechanism of MJF on tumor immu-nology in the treatment of HCC.
AIM OBJECTIVE
To explore the mechanism of action of MJF on tumor immunology in the treatment of HCC.
METHODS METHODS
The absorbable ingredients of MJF were identified using Molecule Network related to High Performance Liquid Chromatography-Electron Spray Ionization-Time of Flight- Mass Spectrometry, and hub potential anti-HCC targets were screened using network pharmacology and pathway enrichment analysis. Forty male mice were randomly divided into the Blank, Model, and MJF groups (1.8, 5.4, and 10.8 g/kg/d) following 7 d of oral administration. Average body weight gain, spleen and thymus indices were calculated, tumor tissues were stained with hematoxylin and eosin, and Interferon gamma (IFN-γ), Tumor necrosis factor α (TNF-α), Interleukin-2, aspartate aminotransferase, alanine aminotransferase, alpha-fetoprotein (AFP), Fas, and FasL were measured by Enzyme-linked Immunosorbent Assay. Relevant mRNA expression of
RESULTS RESULTS
It was shown that MJF improved body weight gain and tumor inhibition rate in H22 tumor-bearing mice, protected immune organs and liver function, reduced the HCC indicator AFP, affected immunity and apoptosis, and up-regulated the TGF-β1/SMAD signaling pathway, by increasing the relative expression of TGF-β1, SMAD2, p-SMAD2 and SMAD4 and decreasing SMAD7, reducing immune factors TNF-α and IFN-γ, decreasing apoptosis cytokines Fas, FasL and
CONCLUSION CONCLUSIONS
MJF inhibits HCC by activating the TGF-β1/SMAD signaling pathway, and affecting immune and apoptotic cytokines, which may be due to MJF adjusting immune escape and apoptosis.

Identifiants

pubmed: 37009316
doi: 10.4251/wjgo.v15.i3.504
pmc: PMC10052660
doi:

Types de publication

Journal Article

Langues

eng

Pagination

504-522

Informations de copyright

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Références

Pharmacogn Mag. 2017 Oct-Dec;13(52):571-575
pubmed: 29200715
Nucleic Acids Res. 2007 Jan;35(Database issue):D727-31
pubmed: 17098932
Planta Med. 2010 Aug;76(11):1118-31
pubmed: 20635308
J Nat Med. 2019 Sep;73(4):800-804
pubmed: 31177356
BMC Genomics. 2011 Nov 30;12 Suppl 3:S3
pubmed: 22369201
Phytomedicine. 2022 Jan 29;98:153963
pubmed: 35121390
J Exp Med. 1995 Jan 1;181(1):71-7
pubmed: 7528780
Anal Bioanal Chem. 2019 Sep;411(22):5785-5797
pubmed: 31236650
Nucleic Acids Res. 2019 Jul 2;47(W1):W357-W364
pubmed: 31106366
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Circ Res. 2012 Oct 26;111(10):1261-73
pubmed: 22912384
J Ethnopharmacol. 2022 Mar 01;285:114887
pubmed: 34864127
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
J Cell Biochem. 2016 Jun;117(6):1279-87
pubmed: 26774024
Hum Pathol. 2001 Mar;32(3):250-6
pubmed: 11274632
Cancers (Basel). 2019 Oct 29;11(11):
pubmed: 31671735
Tumour Biol. 2015 May;36(5):3643-51
pubmed: 25560488
Nat Rev Immunol. 2006 Aug;6(8):595-601
pubmed: 16868550
J Gastroenterol. 2001 Oct;36(10):681-8
pubmed: 11686478
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Nat Prod Rep. 2019 Jul 1;36(7):960-980
pubmed: 31140509
Molecules. 2018 May 17;23(5):
pubmed: 29772791
Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89
pubmed: 21643519
Korean J Radiol. 2019 Jul;20(7):1042-1113
pubmed: 31270974
Nucleic Acids Res. 2020 Jan 8;48(D1):D845-D855
pubmed: 31680165
Cancer. 2020 May 15;126(10):2267-2278
pubmed: 32201944
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Prod Commun. 2014 Nov;9(11):1655-69
pubmed: 25532303
Carbohydr Polym. 2018 Mar 15;184:354-365
pubmed: 29352929
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13135-40
pubmed: 21768356
Curr Opin Genet Dev. 2002 Feb;12(1):22-9
pubmed: 11790550

Auteurs

Yi-Bing Zhang (YB)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.
Department of Clinical Trail Institution Office, Dalian Municipal Central Hospital, Dalian 116033, Liaoning Province, China.

Yong-Rui Bao (YR)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.
Technical Innovation Center of Multidimensional Analysis of Traditional Chinese Medicine of Liaoning Province, Dalian 116600, Liaoning Province, China.
Engineering Laboratory of Modern Chinese Medicine Research of Liaoning Province, Dalian 116600, Liaoning Province, China.

Shuai Wang (S)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.
Technical Innovation Center of Multidimensional Analysis of Traditional Chinese Medicine of Liaoning Province, Dalian 116600, Liaoning Province, China.
Engineering Laboratory of Modern Chinese Medicine Research of Liaoning Province, Dalian 116600, Liaoning Province, China.

Tian-Jiao Li (TJ)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.
Technical Innovation Center of Multidimensional Analysis of Traditional Chinese Medicine of Liaoning Province, Dalian 116600, Liaoning Province, China.
Engineering Laboratory of Modern Chinese Medicine Research of Liaoning Province, Dalian 116600, Liaoning Province, China.

He Tai (H)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.

Jia-Peng Leng (JP)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.

Xin-Xin Yang (XX)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.

Bo-Cai Wang (BC)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.

Xian-Sheng Meng (XS)

College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China.
Technical Innovation Center of Multidimensional Analysis of Traditional Chinese Medicine of Liaoning Province, Dalian 116600, Liaoning Province, China.
Engineering Laboratory of Modern Chinese Medicine Research of Liaoning Province, Dalian 116600, Liaoning Province, China. mxsvvv@163.com.

Classifications MeSH